A Precision Approach to Preserve Kidney Allograft Function
Fibrocor Therapeutics is developing potential first-in-class therapies that target the biological processes driving kidney fibrosis, including fibroblast activation and excessive collagen deposition. Our lead program, FIB992, is being developed with a primary focus on kidney allograft fibrosis (KAF), with the goal of preserving kidney function and extending the functional life of transplanted kidneys.
Our approach combines targets identified through transcriptomic analysis of human kidney biopsies with a clinical development strategy guided by biomarkers. Alport syndrome and chronic kidney disease (CKD) are secondary indications, reflecting the potential to apply our approach across kidney diseases where fibrosis contributes to progressive loss of function.
Primary Focus on Kidney Allograft Fibrosis (KAF)
Kidney allograft fibrosis is the progressive accumulation of scar tissue in a transplanted kidney. This scarring can impair kidney function and contribute to graft failure, leaving patients facing a return to dialysis or another transplant. Although immunosuppressive treatments help control rejection, there remains a need for therapies that address fibrotic damage after transplantation.
Fibrocor’s primary clinical development focus is KAF. Through our collaboration with Professor Maarten Naesens at KU Leuven, we are developing a clinical strategy informed by protocol biopsies and histological endpoints. This work will help define the patient population and guide the evaluation of treatment effects on kidney tissue.
Alport syndrome and CKD remain secondary development priorities. Across these indications, our goal is to slow disease progression and preserve long-term kidney health.
Lean, Experienced Team with a Proven Track Record
Fibrocor is led by a lean, experienced team with deep expertise in fibrosis biology, drug development, clinical strategy and company building. William Newsome, Chief Executive Officer, brings extensive leadership experience across biotechnology, corporate strategy, business development and company growth. Piet Wigerinck, former Chief Scientific Officer at Galapagos, brings more than 30 years of experience, including senior roles at Tibotec and Janssen and contributions to the development of four approved medicines. Paul Ford brings deep expertise in clinical development, biomarker strategy and endpoint design.
Together, the leadership team brings the scientific, clinical and strategic experience needed to advance FIB992 and Fibrocor’s primary focus on KAF, with Alport syndrome and CKD as secondary indications.
Previous collaborations with Galapagos and Otsuka have contributed funding and supported the company’s research and development.
